Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Recurrent Lymphoma: early-phase trial registry

4 of 9 indexed Recurrent Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Recurrent Lymphoma: 9 US clinical trials tracked, 4 recruiting.

Recurrent Lymphoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 3 of these trials.

Enrollment posture brief

Registry condition recurrent-lymphoma

OPEN 4 | RECR 44% | LATE 0 | EARLY 6 | RANK #1916 | SPON 3

Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Recurrent Lymphoma (this)44%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Recurrent Lymphoma

Recurrent Lymphoma lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Lymphoma is recruiting below its size-band peers.

    4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Lymphoma research.

    Children's Oncology Group accounts for 3 of 9 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 63 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. Recurrent Lymphoma splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22

Open and recent trials

9 total, page 1 of 1

RECRUITING 420 participants

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Children's Oncology Group

NCT01790152

RECRUITING 200 participants

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

AIDS Malignancy Consortium

NCT05663502

RECRUITING Phase 2 80 participants

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

NCT03418038

RECRUITING Phase 1 63 participants

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Children's Oncology Group

NCT04870944

ACTIVE NOT RECRUITING 192 participants

Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers

M.D. Anderson Cancer Center

NCT04090619

ACTIVE NOT RECRUITING Phase 1 31 participants

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

NCT05071209

ACTIVE NOT RECRUITING Phase 2 1 participants

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

NCT04320888

COMPLETED Phase 1 59 participants

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Children's Oncology Group

NCT02323880

COMPLETED Phase 1 21 participants

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

National Cancer Institute (NCI)

NCT02780804

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Named interventions

Most-linked intervention names on Recurrent Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pharmacological Study Other
2 trials
Questionnaire Administration Other
2 trials
Laboratory Biomarker Analysis Other
2 trials
Biospecimen Collection Procedure
2 trials
Elimusertib Drug
1 trials
Radionuclide Imaging Procedure
1 trials
FACT Complex-targeting Curaxin CBL0137 Drug
1 trials
Assessment of Therapy Complications Other
1 trials

US sites by state

Facility locations filed on Recurrent Lymphoma trials. A trial with sites in several states counts in each.

California 7 trials
Alabama 6 trials
New York 5 trials
Minnesota 5 trials
Missouri 4 trials
Michigan 4 trials
Massachusetts 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Lymphoma page

9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Lymphoma condition card totals 9 registered trials; most-linked intervention Pharmacological Study; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.